Update shared on23 Sep 2025
Fair value Increased 400%Despite a decrease in net profit margin and a higher future P/E multiple, the consensus analyst price target for Global Medical REIT has surged from $8.97 to $44.84.
What's in the News
- Announced a 1-for-5 reverse stock split, consolidating every five shares into one and paying cash in lieu for fractional shares.
- Amended corporate charter to reflect new share structure with a par value increase to $0.005 per share post-split.
- Launched a $50 million share repurchase program with no expiration date.
- Added to the Russell 2000 Dynamic Index.
Valuation Changes
Summary of Valuation Changes for Global Medical REIT
- The Consensus Analyst Price Target has significantly risen from $8.97 to $44.84.
- The Net Profit Margin for Global Medical REIT has significantly fallen from 4.07% to 3.32%.
- The Future P/E for Global Medical REIT has significantly risen from 123.72x to 142.54x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.